DiaMedica Therapeutics (DMAC) Competitors $4.13 -0.01 (-0.24%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$4.11 -0.02 (-0.48%) As of 05/21/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DMAC vs. NRIX, AVXL, IMNM, RCKT, AVBP, DAWN, TRVI, IMTX, VIR, and SIONShould you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include Nurix Therapeutics (NRIX), Anavex Life Sciences (AVXL), Immunome (IMNM), Rocket Pharmaceuticals (RCKT), ArriVent BioPharma (AVBP), Day One Biopharmaceuticals (DAWN), Trevi Therapeutics (TRVI), Immatics (IMTX), Vir Biotechnology (VIR), and Sionna Therapeutics (SION). These companies are all part of the "pharmaceutical products" industry. DiaMedica Therapeutics vs. Nurix Therapeutics Anavex Life Sciences Immunome Rocket Pharmaceuticals ArriVent BioPharma Day One Biopharmaceuticals Trevi Therapeutics Immatics Vir Biotechnology Sionna Therapeutics Nurix Therapeutics (NASDAQ:NRIX) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and risk. Does the media favor NRIX or DMAC? In the previous week, Nurix Therapeutics had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 14 mentions for Nurix Therapeutics and 13 mentions for DiaMedica Therapeutics. Nurix Therapeutics' average media sentiment score of 1.30 beat DiaMedica Therapeutics' score of 0.71 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 11 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DiaMedica Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders hold more shares of NRIX or DMAC? 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 7.4% of Nurix Therapeutics shares are held by company insiders. Comparatively, 7.3% of DiaMedica Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is NRIX or DMAC more profitable? DiaMedica Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -354.85%. DiaMedica Therapeutics' return on equity of -43.67% beat Nurix Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nurix Therapeutics-354.85% -53.65% -38.59% DiaMedica Therapeutics N/A -43.67%-40.81% Which has higher valuation and earnings, NRIX or DMAC? DiaMedica Therapeutics has lower revenue, but higher earnings than Nurix Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNurix Therapeutics$56.42M13.22-$193.57M-$2.80-3.49DiaMedica TherapeuticsN/AN/A-$19.38M-$0.64-6.45 Do analysts prefer NRIX or DMAC? Nurix Therapeutics currently has a consensus target price of $30.44, indicating a potential upside of 211.29%. DiaMedica Therapeutics has a consensus target price of $8.00, indicating a potential upside of 93.70%. Given Nurix Therapeutics' higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than DiaMedica Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nurix Therapeutics 0 Sell rating(s) 3 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 2.84DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer NRIX or DMAC? DiaMedica Therapeutics received 8 more outperform votes than Nurix Therapeutics when rated by MarketBeat users. However, 78.90% of users gave Nurix Therapeutics an outperform vote while only 63.09% of users gave DiaMedica Therapeutics an outperform vote. CompanyUnderperformOutperformNurix TherapeuticsOutperform Votes8678.90% Underperform Votes2321.10% DiaMedica TherapeuticsOutperform Votes9463.09% Underperform Votes5536.91% Which has more risk and volatility, NRIX or DMAC? Nurix Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. SummaryNurix Therapeutics beats DiaMedica Therapeutics on 10 of the 17 factors compared between the two stocks. Get DiaMedica Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DMAC vs. The Competition Export to ExcelMetricDiaMedica TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$177.11M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-7.378.9226.8419.71Price / SalesN/A250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book3.066.466.794.50Net Income-$19.38M$143.98M$3.23B$248.18M7 Day Performance3.25%3.04%4.07%1.14%1 Month Performance17.00%7.44%12.52%15.20%1 Year Performance35.86%-2.46%16.83%6.56% DiaMedica Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DMACDiaMedica Therapeutics1.4905 of 5 stars$4.13-0.2%$8.00+93.7%+35.9%$177.11MN/A-7.3720News CoverageAnalyst RevisionGap UpNRIXNurix Therapeutics2.4113 of 5 stars$9.51-0.5%$30.44+220.1%-38.6%$725.00M$56.42M-3.29300News CoveragePositive NewsGap UpAVXLAnavex Life Sciences3.7445 of 5 stars$8.44+1.4%$44.00+421.3%+78.9%$720.54MN/A-15.3540IMNMImmunome2.6129 of 5 stars$8.01-0.6%$23.33+191.3%-42.0%$696.97M$10.94M-0.9940Gap DownRCKTRocket Pharmaceuticals4.9061 of 5 stars$6.45-0.8%$37.73+484.9%-70.5%$688.77MN/A-2.35240Gap DownAVBPArriVent BioPharma1.0085 of 5 stars$19.35-0.1%$39.17+102.4%+2.6%$662.02MN/A-5.1340Analyst ForecastDAWNDay One Biopharmaceuticals2.9033 of 5 stars$6.48+3.7%$30.57+371.8%-57.5%$656.83M$161.92M-6.2960Gap UpTRVITrevi Therapeutics3.6014 of 5 stars$6.49-0.2%$17.56+170.6%+126.4%$648.31MN/A-14.7520News CoveragePositive NewsAnalyst ForecastIMTXImmatics2.8222 of 5 stars$5.29+11.6%$17.00+221.4%-51.8%$643M$144.15M-8.02260News CoveragePositive NewsVIRVir Biotechnology3.0922 of 5 stars$4.64+0.9%$32.86+608.1%-55.8%$641.42M$14.30M-1.18580Positive NewsSIONSionna TherapeuticsN/A$14.51+8.0%$38.50+165.3%N/A$640.24MN/A0.0035 Related Companies and Tools Related Companies Nurix Therapeutics Alternatives Anavex Life Sciences Alternatives Immunome Alternatives Rocket Pharmaceuticals Alternatives ArriVent BioPharma Alternatives Day One Biopharmaceuticals Alternatives Trevi Therapeutics Alternatives Immatics Alternatives Vir Biotechnology Alternatives Sionna Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DMAC) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DMAC Stock Free DMAC Stock Alerts